Clinical Trials Directory

Trials / Completed

CompletedNCT03953183

Product Use and Adaptation, Safety and Tolerability of P3P in Adult Healthy Smokers Switching to it

A Randomized, Double-blinded, 2-arm Parallel Groups, Single Center Study to Assess Product Use and Adaptation, Safety and Tolerability of P3P, a Novel Nicotine-containing Product, in Adult Healthy Cigarette Smokers Switching to One of Two P3P Variants for One Month

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Philip Morris Products S.A. · Industry
Sex
All
Age
21 Years – 65 Years
Healthy volunteers
Accepted

Summary

The purpose of the study is to evaluate the product use and adaptation in adult, current cigarette smoking subjects between baseline and after one month of use of one of two P3P variants. The effect of P3P use behavior on nicotine pharmacokinetic (PK) profile, acceptability, as well as the safety and tolerability of P3P over a period of 1 month will be investigated.

Detailed description

This is a study of daily use of up to 15 P3P products over one month, including 2 confinement periods (2 overnight stays at the beginning of the study and 1 overnight stay at the end of the exposure period). During the confinement visits, nicotine PK from P3P exposure will be assessed as well as pharmacodynamic effects related to craving, sensory parameters, product experience, and product acceptance. Between the two confinement periods, subjects will return to the investigational site for weekly ambulatory visits during which P3P will be resupplied and selected safety and other study assessments will be performed. From the start of the exposure period onwards, subjects will be instructed not to smoke or use other tobacco or nicotine containing products and to use P3P exclusively.

Conditions

Interventions

TypeNameDescription
OTHERP3P-1mgP3P-1mg (P3P product containing 1mg of nicotine.)
OTHERP3P-2mgP3P-2mg (P3P product containing 2mg of nicotine.)

Timeline

Start date
2019-04-23
Primary completion
2019-08-14
Completion
2019-10-25
First posted
2019-05-16
Last updated
2020-12-14
Results posted
2020-12-14

Locations

1 site across 1 country: Russia

Source: ClinicalTrials.gov record NCT03953183. Inclusion in this directory is not an endorsement.